Literature DB >> 22614186

131I SPECT/CT in the follow-up of patients with differentiated thyroid carcinoma.

Mareen Menges1, Michael Uder, Torsten Kuwert, Daniela Schmidt.   

Abstract

PURPOSE: 131I SPECT/Spiral-CT has been shown to be superior to planar imaging in staging of differentiated thyroid carcinoma (DTC) at first radioablation. The purpose of this study was to investigate whether this is also true in the further follow-up of patients with DTC.
METHODS: From our clinical database, all patients with DTC who underwent planar scintigraphy as well as SPECT/low-dose spiral CT during follow-up between June 2005 and August 2010 were selected. Iodine-positive foci on the planar images as well as on the SPECT/CT data sets were classified as benign or equivocal/malignant. The criterion standard was provided by histology, other imaging modalities, and clinical and serological follow-up of at least 6 months.
RESULTS: A total of 123 patients with altogether 139 studies met the selection criteria. Whereas the sensitivities of SPECT/CT and planar imaging did not differ significantly (both 62%), the specificity of SPECT/CT was significantly higher than that of planar imaging (98 vs 78%, P < 0.01). SPECT/CT yielded a gain in diagnostic information in 20 (16.3%) of 123 patients (95% confidence interval, 10.8%-23.8%). Hybrid imaging led to a change of diagnosis in none of the patients in whom planar imaging result was normal, in 16% of patients with foci in the neck, and in 26% of patients with extracervical foci.
CONCLUSIONS: In the follow-up of patients with DTC, SPECT/CT significantly improves specificity compared with planar imaging. Incremental diagnostic value is higher in lesions outside the neck than in those in the neck and absent in patients without iodine-positive foci on planar imaging.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614186     DOI: 10.1097/RLU.0b013e3182531dca

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  5 in total

1.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 2.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

3.  Recombinant human thyrotropin versus thyroid hormone withdrawal in differentiated thyroid carcinoma follow-up: a single center experience.

Authors:  M Sahin; B I Aydoğan; E Özkan; R Emral; S Güllü; M F Erdogan; D Çorapçıoğlu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

Review 4.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

Review 5.  SPECT/CT in the Treatment of Differentiated Thyroid Cancer.

Authors:  Sang-Woo Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-02-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.